A phase 1b, randomized, double-blind, placebo-controlled, parallel cohort safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy study of intravenously infused BIIB092 in patients with four different primary tauopathy syndromes.

Peter A. Ljubenkov, Lawren Vandevrede, Julio C. Rojas, Richard Tsai, Mary Koestler, Danielle Graham, Tien Dam, Adam L. Boxer. A phase 1b, randomized, double-blind, placebo-controlled, parallel cohort safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy study of intravenously infused BIIB092 in patients with four different primary tauopathy syndromes. Alzheimer's & Dementia. 2021 Dec 31; 17(S9).